Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TJ-68
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Recipient : Hiroshi Mitsumoto
Deal Size : Inapplicable
Deal Type : Inapplicable
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
Details : TJ-68 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 10, 2021
Lead Product(s) : TJ-68
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Recipient : Hiroshi Mitsumoto
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TU-100
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TU-100 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 08, 2021
Lead Product(s) : TU-100
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rikkunshito
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Recipient : Universitaire Ziekenhuizen KU Leuven
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rikkunshito is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dyspepsia.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 27, 2019
Lead Product(s) : Rikkunshito
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : Universitaire Ziekenhuizen KU Leuven
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daikenchuto
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Cato Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of TU-100 in Patients Undergoing Laparoscopic Colectomy
Details : Daikenchuto is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 05, 2014
Lead Product(s) : Daikenchuto
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Cato Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TU-100
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TU-100 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Irritable Bowel Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 28, 2014
Lead Product(s) : TU-100
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daikenchuto
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Cato Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)
Details : Daikenchuto is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Irritable Bowel Syndrome.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
July 02, 2013
Lead Product(s) : Daikenchuto
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Cato Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TU-100
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
Details : TU-100 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Crohn Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 07, 2011
Lead Product(s) : TU-100
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daikenchuto
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Cato Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of TU-100 in Patients With Functional Constipation
Details : Daikenchuto is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 05, 2011
Lead Product(s) : Daikenchuto
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Cato Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daikenchuto
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Cato Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Daikenchuto is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 08, 2010
Lead Product(s) : Daikenchuto
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Cato Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
